PubMed Health⌕ Search

Biomedical subjects

John B Chambers

Publications and source records attributed to John B Chambers.

4 recordsLinked to original sources

Nominal size in six bileaflet mechanical aortic valves: a comparison of orifice size and biologic equivalence.

OBJECTIVES: Nominal size remains the standard by which valves are compared, but its relationship with orifice area and the patient tissue annulus diameter may differ according to valve design. The aims of this study were to measure the orifice size and compare biologic equivalence in six bileaflet mechanical heart valve designs. METHODS: The inflow aspect of each of 29 valves was photographed then digitized, and the maximum internal diameter and orifice area were calculated. Biologic equivalence was assessed with a series of machined polypropylene blocks. RESULTS: The orifice area ranged between 159 and 222 mm(2) for the six size 19 valves. The internal diameter ranged from 1.6 to 4.6 mm less than the manufacturer's nominal size. Biologic equivalence assessed from an estimate of tissue annulus diameter with machined blocks ranged from 1.0 and 3.5 mm larger than nominal size for the intra-annular valves. This diameter ranged from 3.5 mm smaller to 1.5 mm larger than nominal size for the supra-annular valves. CONCLUSION: There are major differences between nominal size and biologic equivalence. This may lead to confusion when attempting to make comparisons between different valve designs with the same nominal size. A clearer sizing nomenclature is required and could be based on in vitro assessment of tissue annulus diameter or an alphanumeric code.

Aortic Valve↗

Prosthesis-related complications: first-year annual rates.

The rates of valve-related complications determine the clinical performance of biological and mechanical heart valve prostheses by valve position. The crude rates of valve-related complications within the first year after implantation have not been previously reported. The Food and Drug Administration (FDA) of the United States guidance document for the performance of new heart valve prostheses uses objective performance criteria (OPC) as target values for valve-related complications. The FDA requirement for each valve-related complication is that the rate cannot be greater than twice the OPC. This report provides the first-year rates of valve-related complications from a university database of over 7,000 implants, followed longitudinally between 1982 and 1999, of currently marketed biological and mechanical heart valve prostheses. The aim of this report was to provide an additional method for consideration by regulatory authorities in determination of the standards of performance for pre-market approval of new prosthetic valves for heart valve replacement surgery.

Aortic Valve↗

Treatment of left-sided prosthetic valve thrombosis: thrombolysis or surgery?

Although, traditionally, surgery has been the treatment of choice for left-sided prosthetic valve thrombosis (PVT), there are significant risks associated with re-do surgery. Thrombolysis is an alternative to surgery and has a success rate in excess of 80%, but is associated with an -10% risk of systemic embolism and a 7% mortality rate. Guidelines for the use of thrombolytic therapy for PVT were produced using data acquired from older valves, and largely without the use of transesophageal echocardiography (TEE). Data from more recent studies suggest that thrombolysis should be regarded as first-line therapy for PVT in all NYHA classes. The use of TEE is recommended to visualize thrombus in suspected cases.

Echocardiography, Transesophageal↗